124 related articles for article (PubMed ID: 25884646)
1. Toward Labeled Argininamide-Type NPY Y1 Receptor Antagonists: Identification of a Favorable Propionylation Site in BIBO3304.
Keller M; Schindler L; Bernhardt G; Buschauer A
Arch Pharm (Weinheim); 2015 Jun; 348(6):390-8. PubMed ID: 25884646
[TBL] [Abstract][Full Text] [Related]
2. Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous systems: BIB03304 (Y1) and CGP71683A (Y5).
Dumont Y; Cadieux A; Doods H; Fournier A; Quirion R
Can J Physiol Pharmacol; 2000 Feb; 78(2):116-25. PubMed ID: 10737674
[TBL] [Abstract][Full Text] [Related]
3. Dimeric argininamide-type neuropeptide Y receptor antagonists: chiral discrimination between Y1 and Y4 receptors.
Keller M; Kaske M; Holzammer T; Bernhardt G; Buschauer A
Bioorg Med Chem; 2013 Nov; 21(21):6303-22. PubMed ID: 24074877
[TBL] [Abstract][Full Text] [Related]
4. Guanidine-acylguanidine bioisosteric approach in the design of radioligands: synthesis of a tritium-labeled N(G)-propionylargininamide ([3H]-UR-MK114) as a highly potent and selective neuropeptide Y Y1 receptor antagonist.
Keller M; Pop N; Hutzler C; Beck-Sickinger AG; Bernhardt G; Buschauer A
J Med Chem; 2008 Dec; 51(24):8168-72. PubMed ID: 19053784
[TBL] [Abstract][Full Text] [Related]
5. Irreversible binding kinetics of neuropeptide Y ligands to Y2 but not to Y1 and Y5 receptors.
Dautzenberg FM; Neysari S
Pharmacology; 2005 Dec; 75(1):21-9. PubMed ID: 15908753
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships of neuropeptide Y Y1 receptor antagonists related to BIBP 3226.
Aiglstorfer I; Hendrich I; Moser C; Bernhardt G; Dove S; Buschauer A
Bioorg Med Chem Lett; 2000 Jul; 10(14):1597-600. PubMed ID: 10915060
[TBL] [Abstract][Full Text] [Related]
7. N(ω)-Carbamoylation of the Argininamide Moiety: An Avenue to Insurmountable NPY Y1 Receptor Antagonists and a Radiolabeled Selective High-Affinity Molecular Tool ([(3)H]UR-MK299) with Extended Residence Time.
Keller M; Weiss S; Hutzler C; Kuhn KK; Mollereau C; Dukorn S; Schindler L; Bernhardt G; König B; Buschauer A
J Med Chem; 2015 Nov; 58(22):8834-49. PubMed ID: 26466164
[TBL] [Abstract][Full Text] [Related]
8. Application of the guanidine-acylguanidine bioisosteric approach to argininamide-type NPY Y₂ receptor antagonists.
Pluym N; Brennauer A; Keller M; Ziemek R; Pop N; Bernhardt G; Buschauer A
ChemMedChem; 2011 Sep; 6(9):1727-38. PubMed ID: 21692185
[TBL] [Abstract][Full Text] [Related]
9. The ability of neuropeptide Y to mediate responses in the murine cutaneous microvasculature: an analysis of the contribution of Y1 and Y2 receptors.
Chu DQ; Cox HM; Costa SK; Herzog H; Brain SD
Br J Pharmacol; 2003 Sep; 140(2):422-30. PubMed ID: 12970079
[TBL] [Abstract][Full Text] [Related]
10. Red-fluorescent argininamide-type NPY Y1 receptor antagonists as pharmacological tools.
Keller M; Erdmann D; Pop N; Pluym N; Teng S; Bernhardt G; Buschauer A
Bioorg Med Chem; 2011 May; 19(9):2859-78. PubMed ID: 21493077
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP.
Dumont Y; Thakur M; Beck-Sickinger A; Fournier A; Quirion R
Neuropeptides; 2004 Aug; 38(4):163-74. PubMed ID: 15337369
[TBL] [Abstract][Full Text] [Related]
12. Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties.
Gehlert DR; Schober DA; Morin M; Berglund MM
Biochem Pharmacol; 2007 Dec; 74(11):1652-64. PubMed ID: 17897631
[TBL] [Abstract][Full Text] [Related]
13. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
Wieland HA; Willim KD; Entzeroth M; Wienen W; Rudolf K; Eberlein W; Engel W; Doods HN
J Pharmacol Exp Ther; 1995 Oct; 275(1):143-9. PubMed ID: 7562543
[TBL] [Abstract][Full Text] [Related]
14. [(3)H]UR-PLN196: a selective nonpeptide radioligand and insurmountable antagonist for the neuropeptide Y Y(2) receptor.
Pluym N; Baumeister P; Keller M; Bernhardt G; Buschauer A
ChemMedChem; 2013 Apr; 8(4):587-93. PubMed ID: 23361914
[TBL] [Abstract][Full Text] [Related]
15. 1,3-Disubstituted benzazepines as novel, potent, selective neuropeptide Y Y1 receptor antagonists.
Murakami Y; Hara H; Okada T; Hashizume H; Kii M; Ishihara Y; Ishikawa M; Shimamura M; Mihara S; Kato G; Hanasaki K; Hagishita S; Fujimoto M
J Med Chem; 1999 Jul; 42(14):2621-32. PubMed ID: 10411482
[TBL] [Abstract][Full Text] [Related]
16. Mutagenesis of human neuropeptide Y/peptide YY receptor Y2 reveals additional differences to Y1 in interactions with highly conserved ligand positions.
Akerberg H; Fällmar H; Sjödin P; Boukharta L; Gutiérrez-de-Terán H; Lundell I; Mohell N; Larhammar D
Regul Pept; 2010 Aug; 163(1-3):120-9. PubMed ID: 20471432
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and characterization of the first fluorescent nonpeptide NPY Y1 receptor antagonist.
Schneider E; Keller M; Brennauer A; Hoefelschweiger BK; Gross D; Wolfbeis OS; Bernhardt G; Buschauer A
Chembiochem; 2007 Nov; 8(16):1981-8. PubMed ID: 17876753
[TBL] [Abstract][Full Text] [Related]
18. NPY Y1 antagonists: structure-activity relationships of arginine derivatives and hybrid compounds with arpromidine-like partial structures.
Aiglstorfer I; Uffrecht A; Gessele K; Moser C; Schuster A; Merz S; Malawska B; Bernhardt G; Dove S; Buschauer A
Regul Pept; 1998 Sep; 75-76():9-21. PubMed ID: 9802389
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of ligand binding modes at the neuropeptide Y Y
Yang Z; Han S; Keller M; Kaiser A; Bender BJ; Bosse M; Burkert K; Kögler LM; Wifling D; Bernhardt G; Plank N; Littmann T; Schmidt P; Yi C; Li B; Ye S; Zhang R; Xu B; Larhammar D; Stevens RC; Huster D; Meiler J; Zhao Q; Beck-Sickinger AG; Buschauer A; Wu B
Nature; 2018 Apr; 556(7702):520-524. PubMed ID: 29670288
[TBL] [Abstract][Full Text] [Related]
20. Modeling of neuropeptide receptors Y1, Y4, Y5, and docking studies with neuropeptide antagonist.
Jois SD; Nagarajarao LM; Prabhakaran M; Balasubramaniam A
J Biomol Struct Dyn; 2006 Apr; 23(5):497-508. PubMed ID: 16494499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
